Actemra (tocilizumab) has been approved by the U.S. Food and Drug Administration to treat rheumatoid arthritis among people who haven't responded to, or who cannot tolerate, other approved rheumatoid arthritis drugs, the agency said Monday.
Actemra was approved for limited use because of adverse reactions noted in clinical trials, including the possibility of elevated liver enzymes, elevated "bad" cholesterol (LDL), hypertension, and gastrointestinal perforations, the agency said in a news release.
Actemra blocks an immune system protein called interleukin-6, which is found in excess in people with rheumatoid arthritis.
As a condition of the approval, San Francisco-based Genentech, the drug's marketer, must conduct additional clinical studies to evaluate the drug's long-term effectiveness and cardiovascular safety, the FDA said.
The agency said it also is requiring development of a Risk Evaluation and Mitigation Strategy for doctors, to inform physicians on how to monitor patients for possible liver or gastrointestinal side effects.
The most common adverse effects found in clinical testing included upper respiratory infections and other "serious" infections, headache, nasal and sinus inflammation, high blood pressure and increased liver enzymes, the agency said.
The role that diet plays in managing hypertension
10 facts about pets, allergies and kids
Chinese herb for rheumatoid arthritis